News & Events
-
April 1, 2016
Tuberculosis–Advances in Development of New Drugs, Treatment Regimens, Host-Directed Therapies, and Biomarkers
Wallis RS, Maeurer M, Mwaba P, Chakaya J, Rustomjee R, Migliori GB, Marais B, Schito M, Churchyard G, Swaminathan S, Hoelscher M, Zumla A. Tuberculosis–Advances in Development of New Drugs, Treatment Regimens, Host-Directed Therapies, and Biomarkers. The Lancet Infectious Diseases. 2016 Apr;16(4):e34–46.
- March 1, 2016
-
February 26, 2016
Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development
Nuermberger E, Sizemore C, Romero K, Hanna D. Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development. Antimicrobial Agents and Chemotherapy. 2016 Feb 26;60(3):1177–82.
-
December 31, 2015
Evaluation of the Relative Performance of Drug-Induced Skeletal Muscle Injury Biomarkers in Rats
Burch PM, Hall DG, Walker EG, Bracken W, Giovanelli R, Goldstein R, Higgs RE, King NMP, Lane P, Sauer JM, Michna L, Muniappa N, Pritt ML, Vlasakova K, Watson DE, Wescott D, Zabka TS, Glaab WE. Evaluation of the Relative Performance of Drug-Induced Skeletal Muscle Injury Biomarkers in Rats. Toxicological Sciences. 2015 Dec 31.
- December 30, 2015
